Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2020 Earnings Conference Call March 4, 2021 5:00 PM ET Company Participants Mark Namaroff - Executive Director of IR and Corporate Communications Cheryl Blanchard - President and CEO Michael Levitz - EVP, CFO and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Company Mike Petusky - Barrington Research Operator Good evening, ladies and gentlemen, and welcome to Anika's Fourth Quarter and Full Year 2020 Earnings Conference Call. As a reminder, all partic ...

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2020 Earnings Conference Call November 4, 2020 5:00 PM ET Company Participants Kristen Galfetti - IR Cheryl Blanchard - President and CEO Michael Levitz - EVP, CFO and Treasurer Conference Call Participants Jim Sidoti - Sidoti Mike Petusky - Barrington Research Operator Good evening, ladies and gentlemen, and welcome to Anika's Third Quarter 2020 Earnings Conference Call. [Operator Instructions] I will now turn the conference over to Kristen Galfetti, Executive Dire ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-21326 Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3145961 (State or Other Jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-21326 Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3145961 (State or Other Jurisdiction of (I. ...

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q2 2020 Earnings Conference Call July 30, 2020 5:00 PM ET Company Participants Kristen Galfetti - Investor Relations Cheryl Blanchard - President and Chief Executive Officer Sylvia Cheung - Chief Financial Officer Conference Call Participants Jim Sidoti - Sidoti & Company, LLC Michael Petusky - Barrington Research Associates, Inc. Operator Thank you for standing by. This is the conference operator. Welcome to the Q2 2020 Anika Therapeutics Earnings Conference Call. As ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-21326 Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3145961 (State or Other Jurisdiction of (I ...